A Phase 2, Study to Evaluate Prophylactic Interventions on Talquetamab-related oral toxicity - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find the most effective, safe dose of an experimental drug called talquetamab (the study drug) for people with relapsed/refractory multiple myeloma. We want to compare how the study drug works on its own to how it works in combination with different drugs.

What is the Condition Being Studied?

Relapsed or Refractory Multiple Myeloma

Who Can Participate in the Study?

Adults ages 18+ who:

  • Are diagnosed with MM that is not improving with treatment or has come back after treatment
  • Have received previous treatment with a proteasome inhibitor, an immunomodulatory, and an anti-CD38 monoclonal antibody

Para obtener más información sobre quién puede participar en este estudio, comuníquese con el equipo del estudio al 919-668-2556.

What is Involved?

If you decide to participate in this study, you will start a study drug regimen in the following manner:

  • You will take the study drug over the course of 28-day periods called "cycles"
  • During your first cycle, you will get 3 small doses of the study drug 2-4 days apart as a ramp-up to getting a full dose of the study drug on the 15th day of your first cycle.
  • For every cycle after your first, you will get the study drug on the 1st and 15th days of each cycle (every 2 weeks).
  • If you have a good response to the study drug for the first 4 cycles, the study doctor might choose to only give you 1 dose rather than 2 per cycle.

Before you begin taking the study drug, you will get a random assignment (fair, equal chance) to 1 of 4 groups.

  • Group A: If you are in this group, you will take only the study drug.
  • Group B: If you are in this group, you will use dexamethasone mouthwash every day for as long as you are taking the study drug.
  • Group C: If you are in this group, you will take a 50 mg capsule of a drug called pregabalin twice each day for as long as you are taking the study drug.
  • Group D: If you are in this group, you will take a 0.5 mg tablet of a drug called clonazepma twice each day for as long as you are taking the study drug.

Se realizarán las siguientes pruebas y procedimientos a lo largo del estudio:

  • Exámenes físicos
  • Electrocardiograma (ECG), registro de la actividad eléctrica del corazón.
  • Muestra de sangre
  • Potential nutritional consultation
  • Neurological exam
  • Imaging tests (CT, PET/CT and MRI)
  • Biopsia de médula ósea
  • Tongue swabs
  • Cuestionarios
  • Salivary flow test
  • Smell assessments
  • Qualitative interviews

Study Details

Full Title
A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity
Principal Investigator
Especialista en terapia celular
Protocol Number
IRB: PRO00115711
NCT: NCT06500884
Phase
Phase II
ClinicalTrials.gov
Estado de inscripción
Abierto para inscripción